The public health impact of Alzheimer's disease, 2000-2050: Potential implication of treatment advances

Annual Review of Public Health

Volumn 23, Issue , 2002, Pages 213-231

  Sloane, Philip D ^a   Zimmerman, Sheryl ^a   Suchindran, Chirayath ^a   Reed, Peter ^a   Wang, Lily ^a   Boustani, Malaz ^a   Sudha, S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's care; Alzheimer's disease; Public health impact

Indexed keywords

AGED; ALZHEIMER DISEASE; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; FUTUROLOGY; HISTORY OF MEDICINE; HUMAN; OUTPATIENT; PARKINSON DISEASE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; TREATMENT OUTCOME;

ALZHEIMER DISEASE; DISEASE PROGRESSION; FORECASTING; HEALTH CARE COSTS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; PREVALENCE; PUBLIC HEALTH; TREATMENT OUTCOME; UNITED STATES;

EID: 0036250657     PISSN: 01637525     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.publhealth.23.100901.140525     Document Type: Review

References (53)

1. Proxy-reported quality of life in Alzheimer's patients: Comparison of clinical and population-based samples
2. Barinaga Alzheimer's treatments that work now
3. Selegiline for Alzheimer's disease
4. Rivastigmine for Alzheimer's disease
5. Donepezil for mild and moderate Alzheimer's disease
6. Alpha-2 macroglobulin is genetically associated with Alzheimer disease
7. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset
8. Has the survival of the heart failure population changed? Lessons from trials
9. A method for estimating progression rates in Alzheimer disease
10. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy
11. Economic research on Alzheimer disease: A review of the literature
12. The impact of Alzheimer's disease in the United States population
13. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial
14. New insights into genetic and molecular mechanisms of brain degeneration in tauopathies
15. Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Their relevance for understanding the neurogenerative process
16. Age-specific incidence of Alzheimer's disease in a community population
17. The economic impact of tacrine in the treatment of Alzheimer's disease
18. Parkinsonism: Onset, progression, and mortality
19. Survival after the onset of congestive heart failure in Framingham Heart Study subjects
20. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17
21. Evaluation of the costs of caring for the senile demented elderly: A pilot study
22. A new clinical scale for the staging of dementia
23. Long-term tactine (Cognex) treatment: Effects on nursing home placement and mortality
24. Quality of life in Alzheimer's Disease: Patient and caregiver reports
25. Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II
26. Shifting thinking about memory impairment
27. Building a better life: Transforming institutional culture
28. Early-life risk factors and the development of Alzheimer's disease
29. Informal costs of dementia care: Estimates from the national longitudinal caregiver study
30. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
31. The efficacy of Ginkgo biloba on cognitive function in Alzheimer's disease
32. Enzymes point way to potential Alzheimer's therapies
33. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review)
34. The natural history of Parkinson's disease
35. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
36. The economic burden of Alzheimer's disease care
37. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
38. Piecing together Alzheimer's
39. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative study
40. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
41. Translating cell biology into therapeutic advances in Alzheimer's disease
42. Experimental therapeutics of neurodegenerative disorders: Unmet needs
43. A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration
44. A 5-month, randomized, placebo-controlled trial of galantamine in AD
45. Risk factors for Alzheimer's disease: The EURODEM collaborative re-analysis of case-control studies
46. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial